Announcements Trials
Browse Landscape

Phase

Phase 2/3 1Phase 2 1

Status

Recruiting 1Not yet recruiting 1

Sponsor Class

OTHER 84INDUSTRY 32NETWORK 4OTHER_GOV 2NIH 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gynecologic 1Gastrointestinal 1

Conditions

Uterine Cervical Neoplasms 1Gastric Cancer With Liver Metastases 1

Interventions

Capecitabine 6Bevacizumab 5Oxaliplatin 4Radiotherapy 3olaparib 2durvalumab 2dalpiciclib 2atezolizumab 2anlotinib 2Standard of Care 2Radiosurgery 2Leucovorin 2Laparoscopy 2Fluorouracil 2Drug Therapy 2trametinib 1toripalimab 1tislelizumab 1spartalizumab 1pyrotinib 1pomalidomide 1palbociclib 1nilotinib 1ledipasvir, sofosbuvir drug combination 1ledipasvir 1irinotecan sucrosofate 1hetrombopag 1glasdegib 1futibatinib 1fasudil 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
OTHER_GOV × Drug Therapy × 90 days × Clear all
NCT07602140 2026-05-22

TACE Combined With Thermal Ablation and ADC, PD-1, and Chemotherapy as First-line Treatment for HER2-highly-expressing Gastric Cancer With Liver Metastases: A Multicenter, Single-arm Prospective Clinical Study.

Shandong Provincial Hospital

Phase 2 Not yet recruiting
40 enrolled
Gastrointestinal

Gastric Cancer With Liver Metastases

NCT07472153 2026-03-16

PD-1 (Programmed Death-1) Versus PD-L1 (Programmed Death-ligand 1) Immune Check Point Inhibitors Combined With Chemotherapy, With or Without Bevacizumab, In Patients With Metastatic, Persistent Or Recurrent Cervical Cancer

N.N. Alexandrov National Cancer Centre

Phase 2/3 Recruiting
120 enrolled
Gynecologic

Uterine Cervical Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡